UAE Research Institute: Treating diabetes using iPS cells

UAE Research Institute: Treating diabetes using iPS cells

・Jointly developed by Regenefro and UAE Research Institute

・Aiming to spread low-cost treatment methods

We will provide you with a summary of articles published in the Nihon Keizai Shimbun.

Kyoto University Startup: Regenefro

On January 11, a joint research agreement was signed with a research institution in the UAE.

Treatment of diabetes using iPS cells. Develop laws.

Diabetes is said to be common in the Middle East.

Aiming to popularize low-cost treatments that minimize the burden on patients.

Regenefro

Abu Dhabi Stem Cells Center

Kyoto University iPS Cell Research Institute (CiRA)

Abu Dhabi Stem Cells Center is a cell therapy research institute in the UAE.

Signed a three-party agreement with the Kyoto University iPS Cell Research Institute (CiRA).

Diabetic patients in the Middle East:

In the Middle East, there are many patients with obesity and diabetes.

World Health Organization (WHO) report:

According to the 2016 report,

・In the UAE, overweight people account for 70% of the population.

・8% of UAE patients have diabetes.

・The number of diabetic patients in Saudi Arabia reaches 14%.

Developing treatments for type 1 and type 2 diabetes:

Type 1 and type 2 diabetes have different mechanisms of onset.

Develop individual treatments for type 1 and type 2 diabetes.

Treatment for type 2 diabetes:

Type 2 diabetes is more common in obese people.

It occurs when pancreatic cells have difficulty producing insulin, which lowers blood sugar levels.

Developing small molecule drugs:

We will develop small molecule drugs that suppress this decline in cell function.

Creation of pancreatic cells from iPS cells:

Try many drugs and find the most effective one.

Treatment for type 1 diabetes:

In type 1 diabetes, pancreatic cells are destroyed.

Develop a treatment method to generate and replenish pancreatic cells from iPS cells.

Producing pancreatic cells from iPS cells:

Genetically modify iPS cells.

Enable supplementation without the use of immunosuppressants.

Side effects of immunosuppression and decreased quality of life can be avoided.

Radical treatment for type 1 diabetes:

Pancreas transplantation is the definitive treatment for type 1 diabetes, but there is a shortage of organ donors.

If highly functional pancreatic cells can be generated from iPS cells, it may be possible to completely cure many patients.

https://www.nikkei.com/article/DGXZQOUC098420Z00C24A1000000/